Literature DB >> 32488576

The critical role of the interplays of EphrinB2/EphB4 and VEGF in the induction of angiogenesis.

Enming Du1,2,3,4,5,6, Xue Li1,2,3,4,5,6, Siyu He1,2,3,4,5,6, Xiaohua Li7,8,9,10,11,12, Shikun He13,14,15,16.   

Abstract

The significant role of VEGF (vascular endothelial growth factor) as an angiogenesis inducer is well recognized. Besides VEGF, EphrinB2/EphB4 also plays essential roles in vascular development and postnatal angiogenesis. Compared with classical proangiogenic factors, not only does EphrinB2/EphB4 promote sprouting of new vessels, it is also involved in the vessel maturation. Given their involvement in many physiologic and pathological conditions, EphB4 and EphrinB2 are increasingly recognized as attractive therapeutic targets for angiogenesis-related diseases through modulating their expression and function. Previous works mainly focused on the individual role of VEGF and EphrinB2/EphB4 in angiogenesis, respectively, but the correlation between EphrinB2/EphB4 and VEGF in angiogenesis has not been fully disclosed. Here, we summarize the structure and bidirectional signaling of EphrinB2/EphB4, provide an overview on the relationship between EphrinB2/EphB4 signaling and VEGF pathway in angiogenesis and highlight the associated potential usefulness in anti-angiogenetic therapy.

Entities:  

Keywords:  Angiogenesis; EphrinB2/EphB4; VEGF

Mesh:

Substances:

Year:  2020        PMID: 32488576     DOI: 10.1007/s11033-020-05470-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  95 in total

Review 1.  Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development.

Authors:  N W Gale; G D Yancopoulos
Journal:  Genes Dev       Date:  1999-05-01       Impact factor: 11.361

Review 2.  Angiogenesis in life, disease and medicine.

Authors:  Peter Carmeliet
Journal:  Nature       Date:  2005-12-15       Impact factor: 49.962

Review 3.  Molecular regulation of angiogenesis and lymphangiogenesis.

Authors:  Ralf H Adams; Kari Alitalo
Journal:  Nat Rev Mol Cell Biol       Date:  2007-06       Impact factor: 94.444

Review 4.  Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis.

Authors:  Ombretta Salvucci; Giovanna Tosato
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 5.  Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.

Authors:  Jonathan Welti; Sonja Loges; Stefanie Dimmeler; Peter Carmeliet
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

6.  The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.

Authors:  Christopher M Adams; Karen Anderson; Gerald Artman; Jean-Claude Bizec; Rosemarie Cepeda; Jason Elliott; Elizabeth Fassbender; Malay Ghosh; Shawn Hanks; Leo A Hardegger; Vinayak P Hosagrahara; Bruce Jaffee; Keith Jendza; Nan Ji; Leland Johnson; Wendy Lee; Donglei Liu; Fang Liu; Debby Long; Fupeng Ma; Nello Mainolfi; Erik L Meredith; Karl Miranda; Yao Peng; Stephen Poor; James Powers; Yubin Qiu; Chang Rao; Siyuan Shen; Jeremy M Sivak; Catherine Solovay; Peter Tarsa; Amber Woolfenden; Chun Zhang; Yiqin Zhang
Journal:  J Med Chem       Date:  2018-02-05       Impact factor: 7.446

7.  Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth.

Authors:  María Angeles Abéngozar; Sergio de Frutos; Sergio Ferreiro; Joaquím Soriano; Manuel Perez-Martinez; David Olmeda; Marco Marenchino; Marta Cañamero; Sagrario Ortega; Diego Megias; Antonio Rodriguez; Jorge L Martínez-Torrecuadrada
Journal:  Blood       Date:  2012-03-23       Impact factor: 22.113

Review 8.  Eph receptors and ephrins: therapeutic opportunities.

Authors:  Antonio Barquilla; Elena B Pasquale
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-03       Impact factor: 13.820

Review 9.  Mechanisms of ocular angiogenesis and its molecular mediators.

Authors:  Martin J Siemerink; Albert J Augustin; Reinier O Schlingemann
Journal:  Dev Ophthalmol       Date:  2010-08-10

Review 10.  Endothelial tip cells in ocular angiogenesis: potential target for anti-angiogenesis therapy.

Authors:  Martin J Siemerink; Ingeborg Klaassen; Cornelis J F Van Noorden; Reinier O Schlingemann
Journal:  J Histochem Cytochem       Date:  2012-10-23       Impact factor: 2.479

View more
  6 in total

Review 1.  The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer.

Authors:  Xinyi Wang; Jing Huang; Wenjie Chen; Genpeng Li; Zhihui Li; Jianyong Lei
Journal:  Exp Mol Med       Date:  2022-09-22       Impact factor: 12.153

2.  Inhibition of laser induced rats choroidal neovascularization by intravitreous injection of sEphB4-HSA.

Authors:  Shikun He; Sha Ouyang; Xiaohua Li; Binyun Ma
Journal:  Ann Transl Med       Date:  2021-01

Review 3.  EphrinB2-EphB4 Signaling in Neurooncological Disease.

Authors:  Andras Piffko; Christian Uhl; Peter Vajkoczy; Marcus Czabanka; Thomas Broggini
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

4.  The Consequences of Soluble Epoxide Hydrolase Deletion on Tumorigenesis and Metastasis in a Mouse Model of Breast Cancer.

Authors:  Rushendhiran Kesavan; Timo Frömel; Sven Zukunft; Bernhard Brüne; Andreas Weigert; Ilka Wittig; Rüdiger Popp; Ingrid Fleming
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

Review 5.  Eph Receptors and Ephrins in Retinal Diseases.

Authors:  Radoslaw Kaczmarek; Pawel Gajdzis; Malgorzata Gajdzis
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

6.  Hit Identification of a Novel Quinazoline Sulfonamide as a Promising EphB3 Inhibitor: Design, Virtual Combinatorial Library, Synthesis, Biological Evaluation, and Docking Simulation Studies.

Authors:  Kyeong Lee; Hossam Nada; Hyun Jung Byun; Chang Hoon Lee; Ahmed Elkamhawy
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.